| Revenue growth | 133% YoY consolidated growth in FY26. |
|---|---|
| Margins | Targeting 17% EBITDA margin for FY27. |
| Demand visibility | Strong; 50% revenue from long-term supply contracts. |
| Management confidence | High; projecting ₹750cr revenue for FY27. |
Growth
FY26 consolidated revenue rose 133% to ₹381cr; Standalone revenue grew 30% to ₹162cr with PAT up 64%.
Outlook
FY27 revenue guidance of ₹750cr with 17% EBITDA margin. Ongoing ₹440cr capex program for India and Australia.
Risks
H1 performance typically weaker (40% vs 60% in H2); reliance on CMOs until Australian facility commissioning.
Earnings Call filed with NSE, NSE: SAIPARENT. Summary written with AI assistance from the document.
Sai Parenterals Ltd: key numbers
- Share price
- ₹521.65
- Market cap
- ₹2,305 Cr
- Revenue (annual)
- ₹381.0 Cr
- Net profit (annual)
- ₹14.26 Cr
- P/E (TTM)
- 111.0×Sector 47.3×
- Promoter holding
- 51.16%+0.00% QoQ
- FII holding
- 4.03%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Sai Parenterals Ltd
All →Sai Parenterals Annual General Meeting
Sai Parenterals held its 25th Annual General Meeting on September 10, 2026. Shareholders approved financial statements, director appointments, and various company resolutions.
Sai Parenterals Bags ₹204 Cr Order
Sai Parenterals' subsidiary, Noumed Pharmaceuticals, renewed a 3-year OTC Medicines Supply Agreement with an Australian pharmacy chain, valued at approximately ₹204 Crore.
- Value
- ₹204.0 Cr
- Execution
- 3 years
Sai Parenterals Annual Report
Sai Parenterals Ltd submitted its 25th Annual Report for FY 2025-26 to the stock exchanges as required under SEBI (LODR) regulations.
Sai Parenterals Annual General Meeting
Sai Parenterals Limited has submitted the notice for its 25th Annual General Meeting, scheduled to be held on 10th September, 2026 via video conference.
Sai Parenterals Earnings Call Transcript: Key Takeaways
Management is pivoting to acquisitions after regulatory shifts blocked organic expansion in Hyderabad. While revenue growth appears strong due to the Numed consolidation, margins were hurt by high logistics costs in Australia.
Sai Parenterals Merger & Restructuring Worth ₹15 Cr
Sai Parenterals Limited will acquire a 60% stake in Prathyuk Laboratories Private Limited for ₹15 Crore. This strategic move secures an established R&D setup in the pharma sector.
- Value
- ₹15.00 Cr